Home Featured 2

Featured 2

Featured posts

Latest

Expanding Efforts Help Address Disparities in Lung Cancer Care

lungcanc

SHAWL: Largest Study of Its Kind Evaluates Sexual Dysfunction in Women With Lung Cancer

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?

Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

Consolidating Gains with Chemotherapy in SCLC Maintenance Trials: A Discussion with...

lungcanc

Ireland’s Complex Healthcare System and Its Relation to Innovative Ways for...

lungcanc

$Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with Dr. Mark Socinski$

Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with...

lungcanc

Making Headway with Lorlatinib

lungcanc

Korean Lung Cancer Screening Project (K-LUCAS) Led to Launch of New...

lungcanc

KEYNOTE-010: Long-Term Outcomes and Results of Retreatment

lungcanc

Can E-Cigarettes Help Patients Stop Smoking Combustible Cigarettes?

lungcanc

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS...

lungcanc

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

lungcanc

Paul Bunn

The Peaks and Valleys in Lung Cancer Therapeutics Research

lungcanc

1...456 7 Page 5 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib